Evaluation of the antidiabetic effects of dipeptidyl peptidase-IV inhibitor ASP8497 in streptozotocin-nicotinamide-induced mildly diabetic mice

Pharmacology

Volumn 83, Issue 3, 2009, Pages 177-187

  Tahara, Atsuo ^a   Matsuyama Yokono, Akiko ^a   Nakano, Ryosuke ^a   Someya, Yuka ^a   Hayakawa, Masahiko ^a   Shibasaki, Masayuki ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

ASP8497; Blood glucose; Diabetes; Dipeptidyl peptidase IV; Glucagon like peptide 1; Insulin

Indexed keywords

4 FLUORO 1 [[(4 METHYL 1 METHYLSULFONYLPIPERIDIN 4 YL)AMINO]ACETYL]PYRROLIDINE 2 CARBONITRILE MONOFUMARATE; ASP 8497; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; NICOTINAMIDE; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANTIGENS, CD26; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DRUG EVALUATION, PRECLINICAL; FASTING; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; INSULIN; MALE; MICE; MICE, INBRED ICR; PANCREAS; PIPERIDINES; PYRROLIDINES;

EID: 58749113105     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000196813     Document Type: Article

References (27)

1. Smyth S, Heron A: Diabetes and obesity: the twin epidemics. Nat Med 2006;12:75-80.
2. Polonsky KS, Given BD, Hirsch LJ, Tillil H, Shapiro ET, Beebe C, Frank BH, Galloway JA, Van Cauter E: Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1998;318:1231-1239.
3. Taylor SI, Accili D, Imai Y: Insulin resistance or insulin deficiency. Which is the primary cause of NIDDM? Diabetes 1994;43:735-740.
4. Cavaghan MK, Ehrmann DA, Polonsky KS: Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest 2000;106:329-333.
5. Holman RR: Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective. Metabolism 2006;55:S2-S5.
6. Stahl M, Berger W: Higher incidence of severe hypoglycaemia leading to hospital admission in type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas. Diabet Med 1999;16:586-590.
7. Holst JJ: Enteroglucagon. Annu Rev Physiol 1997;59:257-271.
8. MacDonald PE, El-Kholy W, Riedel MJ, Salapatek AM, Light PE, Wheeler MB: The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 2002;51:S434-S442.
9. Kieffer TJ, McIntosh CH, Pederson RA: Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995;136:3585-3596.
10. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ: Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH 2 -terminus in type II diabetic patients and in healthy subjects. Diabetes 1995;44:1126-1131.
11. Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CH, Demuth HU: Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 1998;47:1253-1258.
12. Reimer MK, Holst JJ, Ahren B: Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol 2002;146:717-727.
13. Burkey BF, Li X, Bolognese L, Balkan B, Mone M, Russell M, Hughes TE, Wang PR: Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. J Pharmacol Exp Ther 2005;315:688-695.
14. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H: Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564-2571.
15. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A: Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, doubleblind, randomized trial. Diabetes Care 2007;30:217-223.
16. Someya Y, Tahara A, Nakano R, Matsuyama-Yokono A, Nagase I, Fukunaga Y, Takasu T, Hayakawa M, Shibasaki M: Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol 2008;377:209-217.
17. Villhauer EB, Brinkman JA, Naderi GB, Burkey BF, Dunning BE, Prasad K, Mangold BL, Russell ME, Hughes TE:1-[[3-hydroxy-1-adamantyl]amino]acetyl]-2- cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003;46:2774-2789.
18. Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey GJ, Kowalchick JE, Leiting B, Lyons K, Marsilio F, McCann ME, Patel RA, Petrov A, Scapin G, Patel SB, Roy RS, Wu JK, Wyvratt MJ, Zhang BB, Zhu L, Thornberry NA, Weber AE: (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a] pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005;48:141-151.
19. Augeri DJ, Robl JA, Betebenner DA, Magnin DR, Khanna A, Robertson JG, Wang A, Simpkins LM, Taunk P, Huang Q, Han SP, Abboa-Offei B, Cap M, Xin L, Tao L, Tozzo E, Welzel GE, Egan DM, Marcinkeviciene J, Chang SY, Biller SA, Kirby MS, Parker RA, Hamann LG: Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, longacting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005;48:5025-5037.
20. Tahara A, Matsuyama-Yokono A, Nakano R, Someya Y, Shibasaki M: Effects of antidiabetic drugs on glucose tolerance in streptozotocin-nicotinamide-induced mildly diabetic and streptozotocin-induced severely diabetic mice. Horm Metab Res 2008; in press.
21. Lu WJ, Yang Q, Sun W, Woods SC, D'Alessio D, Tso P: The regulation of the lymphatic secretion of glucagon-like peptide-1 (GLP-1) by intestinal absorption of fat and carbohydrate. Am J Physiol 2007;293:G961-G971.
22. Lankas GR, Leiting B, Roy RS, Eiermann GJ, Beconi MG, Biftu T, Chan CC, Edmondson S, Feeney WP, He H, Ippolito DE, Kim D, Lyons KA, Ok HO, Patel RA, Petrov AN, Pryor KA, Qian X, Reigle L, Woods A, Wu JK, Zaller D, Zhang X, Zhu L, Weber AE, Thornberry NA: Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidase 8 and 9. Diabetes 2005;54:2988-2994.
23. Matsuyama-Yokono A, Tahara A, Nakano R, Someya Y, Nagase I, Hayakawa M, Shibasaki M: ASP8497 is a novel selective and competitive dipeptidyl peptidase-IV inhibitor with antihyperglycemic activity. Biochem Pharmacol 2008;76:98-107.
24. Horrower AD: Comparison of efficacy, secondary failure rate, and complications of sulfonylureas. J Diabetes Complications 1994;8:201-203.
25. Pontiroli AE, Calderara A, Pozza G: Secondary failure of oral hypoglycaemic agents: frequency, possible causes, and management. Diabetes Metab Rev 1994;10:31-43.
26. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC: UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. Diabet Med 1998;15:297-303.
27. Matsuyama-Yokono A, Tahara A, Nakano R, Someya Y, Shiraki K, Hayakawa M, Shibasaki M: Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice. Metabolism; in press.